Market Cap 1.66B
Revenue (ttm) 75.13M
Net Income (ttm) -146.41M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -194.88%
Debt to Equity Ratio 0.00
Volume 5,652,900
Avg Vol 7,242,618
Day's Range N/A - N/A
Shares Out 305.38M
Stochastic %K 16%
Beta 1.17
Analysts Strong Sell
Price Target $10.43

Company Profile

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a researc...

Industry: Biotechnology
Sector: Healthcare
Phone: 604 559 9005
Address:
150 W 4th Avenue, Vancouver, Canada
tradersunion353
tradersunion353 Jun. 10 at 2:13 AM
$ABCL Clowns here get too excited cheerleading dancing when ever stock drops.. not sure what kind of annoying traders are these pumpers. This overhyped junk lost 87% share value in 5 years.
0 · Reply
MorganHoratio
MorganHoratio Jun. 9 at 11:32 PM
During this market downturn, please pay attention to the following stocks: Health: $ABCL $VKTX $HIMS $TXG $CRSP An exceptional high-alpha radar for the healthcare sector! This local macro consolidation is providing a premium entry zone for true clinical disrupters and digital health compounders. The fundamental catalysts driving this group are deeply institutional. HIMS is a standout hyper-growth monster, surging over 6% into the $28 node backed by relentless expansion in its customized weight-loss workstreams and explosive net income inflections. VKTX represents an elite macro-accumulation play ahead of its critical oral obesity data milestones, while CRSP and TXG (10x Genomics) lock in structural, irreplaceable moats across gene-editing and spatial biology instrumentation. As capital rotates into high-conviction health tech, are you compounding shares in the immediate cash-flow powerhouse HIMS, or front-running the technical floors on VKTX and CRSP?
0 · Reply
tradersunion353
tradersunion353 Jun. 9 at 9:15 PM
$ABCL what a POS stock overhyped junk for phase 1 data this POS dropped 30% after phase 2 data this garbage is mostly likely gonna drop to 2 dollars
0 · Reply
Cassek86
Cassek86 Jun. 9 at 6:23 PM
$ABCL Nice recovery for an „overhyped“ stock.
0 · Reply
tradersunion353
tradersunion353 Jun. 9 at 5:17 PM
$ABCL Overhyped junk. Heading to 1 dollar
0 · Reply
tradersunion353
tradersunion353 Jun. 9 at 5:17 PM
$ABCL Demamp and his p*** adders and loader will be like We are adding and loading - Losers
0 · Reply
Plutten1973
Plutten1973 Jun. 9 at 4:27 PM
$ABCL no big deal used to it still over 3 life is wonderful cheers to everyone
0 · Reply
Ed_Ng
Ed_Ng Jun. 9 at 3:33 PM
$ABCL agree. Why bought at top? lol
1 · Reply
tradersunion353
tradersunion353 Jun. 9 at 2:33 PM
$ABCL overhyped junk
0 · Reply
tkstockpicker
tkstockpicker Jun. 9 at 2:20 PM
$ABCL LOL, idiot
1 · Reply
Latest News on ABCL
AbCellera appoints Victor Sandor to board of directors

2026-06-05T13:05:56.000Z - 4 days ago

AbCellera appoints Victor Sandor to board of directors


AbCellera price target raised to $8 from $7 at Stifel

2026-05-12T10:58:11.000Z - 4 weeks ago

AbCellera price target raised to $8 from $7 at Stifel


AbCellera Biologics Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 weeks ago

AbCellera Biologics Earnings Call Transcript: Q1 2026


AbCellera Biologics Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 weeks ago

AbCellera Biologics Earnings release: Q1 2026


AbCellera Biologics Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 weeks ago

AbCellera Biologics Quarterly report: Q1 2026


AbCellera Biologics Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 4 weeks ago

AbCellera Biologics Slides: Q1 2026


AbCellera initiated with an Overweight at Cantor Fitzgerald

2026-05-05T10:36:31.000Z - 5 weeks ago

AbCellera initiated with an Overweight at Cantor Fitzgerald


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera Biologics Proxy statement: Proxy filing

Apr 29, 2026, 8:00 AM EDT - 5 weeks ago

AbCellera Biologics Proxy statement: Proxy filing


AbCellera initiated with a Buy at JonesResearch

2026-04-09T20:10:26.000Z - 2 months ago

AbCellera initiated with a Buy at JonesResearch


AbCellera Biologics Earnings Call Transcript: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings Call Transcript: Q4 2025


AbCellera Biologics Annual report: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Annual report: Q4 2025


AbCellera Biologics Earnings release: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Earnings release: Q4 2025


AbCellera Biologics Slides: Q4 2025

Feb 24, 2026, 5:00 PM EST - 3 months ago

AbCellera Biologics Slides: Q4 2025


AbCellera reports FY25 EPS (49c) vs. (55c) last year

2026-02-24T21:15:21.000Z - 3 months ago

AbCellera reports FY25 EPS (49c) vs. (55c) last year


AbCellera Reports Full Year 2025 Business Results

Feb 24, 2026, 4:05 PM EST - 3 months ago

AbCellera Reports Full Year 2025 Business Results


AbCellera Biologics Slides: Corporate presentation

Jan 14, 2026, 7:00 AM EST - 5 months ago

AbCellera Biologics Slides: Corporate presentation


AbCellera Appoints Dr. Stephen Quake to its Board of Directors

Nov 10, 2025, 9:00 AM EST - 7 months ago

AbCellera Appoints Dr. Stephen Quake to its Board of Directors


AbCellera Biologics Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings Call Transcript: Q3 2025


AbCellera Biologics Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Quarterly report: Q3 2025


AbCellera Biologics Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Earnings release: Q3 2025


AbCellera Biologics Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

AbCellera Biologics Slides: Q3 2025


AbCellera Reports Q3 2025 Business Results

Nov 6, 2025, 4:05 PM EST - 7 months ago

AbCellera Reports Q3 2025 Business Results


AbCellera appoints Sarah Noonberg as Chief Medical Officer

2025-09-10T13:20:54.000Z - 9 months ago

AbCellera appoints Sarah Noonberg as Chief Medical Officer

MGX


AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer

Sep 10, 2025, 9:07 AM EDT - 9 months ago

AbCellera Appoints Dr. Sarah Noonberg as Chief Medical Officer


AbCellera doses first participants in Phase 1 trial of ABCL575

2025-08-27T13:20:26.000Z - 10 months ago

AbCellera doses first participants in Phase 1 trial of ABCL575


AbCellera price target raised to $7 from $5 at BMO Capital

2025-08-08T13:26:29.000Z - 10 months ago

AbCellera price target raised to $7 from $5 at BMO Capital


AbCellera Biologics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings Call Transcript: Q2 2025


AbCellera Biologics Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Quarterly report: Q2 2025


AbCellera Biologics Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Earnings release: Q2 2025


AbCellera Biologics Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 10 months ago

AbCellera Biologics Slides: Q2 2025


AbCellera Biologics Slides: Corporate Presentation

Aug 1, 2025, 7:00 AM EDT - 11 months ago

AbCellera Biologics Slides: Corporate Presentation


AbCellera assumed with an Outperform at Leerink

2025-07-07T10:40:33.000Z - 1 year ago

AbCellera assumed with an Outperform at Leerink


AbCellera Biologics Earnings Call Transcript: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q1 2025


AbCellera Biologics Earnings release: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Earnings release: Q1 2025


AbCellera Biologics Quarterly report: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Quarterly report: Q1 2025


AbCellera Biologics Slides: Q1 2025

May 8, 2025, 5:00 PM EDT - 1 year ago

AbCellera Biologics Slides: Q1 2025


AbCellera Reports Q1 2025 Business Results

May 8, 2025, 4:05 PM EDT - 1 year ago

AbCellera Reports Q1 2025 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2025, 8:00 AM EDT - 1 year ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q4 2024


AbCellera Biologics Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q4 2024


AbCellera Biologics Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Annual report: Q4 2024


AbCellera Biologics Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q4 2024


AbCellera Reports Full Year 2024 Business Results

Feb 27, 2025, 4:05 PM EST - 1 year ago

AbCellera Reports Full Year 2024 Business Results


AbCellera Biologics Slides: FY 2025

Jan 15, 2025, 7:30 PM EST - 1 year ago

AbCellera Biologics Slides: FY 2025


AbCellera Biologics Earnings Call Transcript: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings Call Transcript: Q3 2024


AbCellera Biologics Quarterly report: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Quarterly report: Q3 2024


AbCellera Biologics Earnings release: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Earnings release: Q3 2024


AbCellera Biologics Slides: Q3 2024

Nov 4, 2024, 5:00 PM EST - 1 year ago

AbCellera Biologics Slides: Q3 2024


AbCellera Reports Q3 2024 Business Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

AbCellera Reports Q3 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q2 2024


AbCellera Biologics Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q2 2024


AbCellera Biologics Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q2 2024


AbCellera Biologics Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q2 2024


AbCellera Reports Q2 2024 Business Results

Aug 6, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q2 2024 Business Results


AbCellera Biologics Earnings Call Transcript: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings Call Transcript: Q1 2024


AbCellera Biologics Quarterly report: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Quarterly report: Q1 2024


AbCellera Biologics Earnings release: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Earnings release: Q1 2024


AbCellera Biologics Slides: Q1 2024

May 7, 2024, 5:00 PM EDT - 2 years ago

AbCellera Biologics Slides: Q1 2024


AbCellera Reports Q1 2024 Business Results

May 7, 2024, 4:05 PM EDT - 2 years ago

AbCellera Reports Q1 2024 Business Results


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


AbCellera Biologics Proxy statement: Proxy Filing

Apr 29, 2024, 8:00 AM EDT - 2 years ago

AbCellera Biologics Proxy statement: Proxy Filing


tradersunion353
tradersunion353 Jun. 10 at 2:13 AM
$ABCL Clowns here get too excited cheerleading dancing when ever stock drops.. not sure what kind of annoying traders are these pumpers. This overhyped junk lost 87% share value in 5 years.
0 · Reply
MorganHoratio
MorganHoratio Jun. 9 at 11:32 PM
During this market downturn, please pay attention to the following stocks: Health: $ABCL $VKTX $HIMS $TXG $CRSP An exceptional high-alpha radar for the healthcare sector! This local macro consolidation is providing a premium entry zone for true clinical disrupters and digital health compounders. The fundamental catalysts driving this group are deeply institutional. HIMS is a standout hyper-growth monster, surging over 6% into the $28 node backed by relentless expansion in its customized weight-loss workstreams and explosive net income inflections. VKTX represents an elite macro-accumulation play ahead of its critical oral obesity data milestones, while CRSP and TXG (10x Genomics) lock in structural, irreplaceable moats across gene-editing and spatial biology instrumentation. As capital rotates into high-conviction health tech, are you compounding shares in the immediate cash-flow powerhouse HIMS, or front-running the technical floors on VKTX and CRSP?
0 · Reply
tradersunion353
tradersunion353 Jun. 9 at 9:15 PM
$ABCL what a POS stock overhyped junk for phase 1 data this POS dropped 30% after phase 2 data this garbage is mostly likely gonna drop to 2 dollars
0 · Reply
Cassek86
Cassek86 Jun. 9 at 6:23 PM
$ABCL Nice recovery for an „overhyped“ stock.
0 · Reply
tradersunion353
tradersunion353 Jun. 9 at 5:17 PM
$ABCL Overhyped junk. Heading to 1 dollar
0 · Reply
tradersunion353
tradersunion353 Jun. 9 at 5:17 PM
$ABCL Demamp and his p*** adders and loader will be like We are adding and loading - Losers
0 · Reply
Plutten1973
Plutten1973 Jun. 9 at 4:27 PM
$ABCL no big deal used to it still over 3 life is wonderful cheers to everyone
0 · Reply
Ed_Ng
Ed_Ng Jun. 9 at 3:33 PM
$ABCL agree. Why bought at top? lol
1 · Reply
tradersunion353
tradersunion353 Jun. 9 at 2:33 PM
$ABCL overhyped junk
0 · Reply
tkstockpicker
tkstockpicker Jun. 9 at 2:20 PM
$ABCL LOL, idiot
1 · Reply
tkstockpicker
tkstockpicker Jun. 9 at 1:56 PM
$ABCL bought
0 · Reply
bonecrack_benny
bonecrack_benny Jun. 9 at 12:35 PM
$ABCL biotech summer festival 2026
0 · Reply
tradersunion353
tradersunion353 Jun. 8 at 11:16 PM
$ABCL so it was a 2 day show.. and back to where it belongs to overhyped under performing junk
0 · Reply
ChipDistribution7
ChipDistribution7 Jun. 8 at 10:13 PM
$ABCL Price is following the plan: made a lower low and approaching the 200-week moving average A break below this level could push it straight into the key buy zone Wave 5 target remains around 165% from current levels
1 · Reply
Samb2344
Samb2344 Jun. 8 at 10:04 PM
$ABCL you all worry to much and need to know patience 🤧
0 · Reply
tradersunion353
tradersunion353 Jun. 8 at 8:15 PM
$ABCL what a ugly pos performance JUnk stock
0 · Reply
tranq19
tranq19 Jun. 8 at 8:00 PM
$ABCL is it Q3 yet? Can’t avoid watching every day but I’m fully loaded and it does not matter. It’s either going to be 2-3 or 15-25 in a month or two. Unless I don’t understand the science, seems to me like either it works or it doesn’t (blocking nk3r outside blood brain barrier alone).
0 · Reply
tradersunion353
tradersunion353 Jun. 8 at 5:36 PM
$ABCL Phase 2 data is bad? Why would any stock keeps falling almost every week? CLowns how is your adding and loading working on this overhyped junk?
1 · Reply
Samb2344
Samb2344 Jun. 8 at 5:28 PM
$ABCL I added more so stop complaining and buy put ya money were ya mouth is 🤧
1 · Reply
oceanbleu
oceanbleu Jun. 8 at 4:37 PM
$ABCL I posted this weekly chart last week with the recommended profit taking at 6.72$ for a 125% trade. The closest support is at 4.4$ and the closest untested is at 5.2$. A daily regain could occur atr 5.2-5.6 area however given it bear regained the weekly 6.3-6.7 , the pullback could be more significant (ie 3.9$ ish level)
0 · Reply
tradersunion353
tradersunion353 Jun. 8 at 4:08 PM
$ABCL Adding and loading clowns are back They are always happy if this garbage stock drops, Ovberhyped junk
0 · Reply